The authors examine advances in the design and the application of biological indicator evaluator resistometer vessels used to measure the resistance of bacterial spores in monitoring sterilization processes.
Aug 2, 2007
By:
Kurt McCauley, John R. Gillis, James P. Agalloco
The authors examine advances in the design and the application of biological indicator evaluator resistometer vessels used to measure the resistance of bacterial spores in monitoring sterilization processes.
|
Aseptic processing has advanced over the past several decades, yet the pharmaceutical industry is still accepting of its limitations, particularly as it relates to human intervention as a source of contamination. The authors explain the importance of further diminishing the role of operators in aseptic processing and the approaches and technologies needed to achieve that goal.
May 1, 2007
By:
James E. Akers, James P. Agalloco
Aseptic processing has advanced over the past several decades, yet the pharmaceutical industry is still accepting of its limitations, particularly as it relates to human intervention as a source of contamination. The authors explain the importance of further diminishing the role of operators in aseptic processing and the approaches and technologies needed to achieve that goal.
|
The author clarifies the definition and objectives of overkill sterilization for steam sterilization cycles. Current sterilization practices are reviewed and the validation difficulties associated with the various definitions of overkill sterilization are explored.
May 1, 2007
By:
James P. Agalloco
The author clarifies the definition and objectives of overkill sterilization for steam sterilization cycles. Current sterilization practices are reviewed and the validation difficulties associated with the various definitions of overkill sterilization are explored.
|
This article summarizes changes to the Akers–Agalloco aseptic processing risk analysis model (first presented in Pharmaceutical Technology's November 2005 issue) as well as some of the underlying thinking behind the revision. The simplified model makes the method easier to use because of its greater flexibility of environmental control practice. It maintains the emphasis on human activity as the primary consideration in risk management for aseptic processing.
Jul 2, 2006
By:
James E. Akers, James P. Agalloco
This article summarizes changes to the Akers–Agalloco aseptic processing risk analysis model (first presented in Pharmaceutical Technology's November 2005 issue) as well as some of the underlying thinking behind the revision. The simplified model makes the method easier to use because of its greater flexibility of environmental control practice. It maintains the emphasis on human activity as the primary consideration in risk management for aseptic processing.
|
May 1, 2006
By:
James P. Agalloco, James E. Akers
Any aseptic processing technology that allows intervention by
gowned personnel during operation cannot be considered an advanced
technology. Although a standardized definition of restricted access
barrier systems has been developed, these systems fall well short
of being classfied as advanced technologies.
|
May 1, 2006
By:
James P. Agalloco
There are few, if any, valid reasons not to install an isolator in a new aseptic processing facility.
|
Nov 2, 2005
By:
James E. Akers, James P. Agalloco
The authors present a new approach to risk assessment for aseptic processing that emphasizes the contributions of personnel.
|
May 1, 2005
By:
James P. Agalloco, James E. Akers
The complete elimination of human-derived contamination is possible only with the elimination of human intervention.
|
Apr 2, 2005
By:
James P. Agalloco
The sterility testing of samples from an aseptic process may be considered an entirely separate aseptic process that is subject to the same types of adventitious contamination as the aseptic process itself.
|
|
